| Long-term safety and efficacy of adalimumab for intestinal Behçet's disease |
|
|
|
This issue chosen by the Editor of Intestinal Research is the open label study following a phase 3 clinical trial about long-term safety and efficacy of adalimumab for intestinal Behçet's disease (BD) performed by Inoue et al.
Previously, 52 week results of a phase 3 clinical study demonstrating the efficacy and safety of adalimumab in intestinal BD was reported in the same group. Based on this open-label clinical trial, adalimumab was recently approved and recommended as a standard therapy for intestinal BD in Japan, Taiwan and South Korea.
In this study, Inoue et al. evaluated safety profile and effectiveness of adalimumab for the treatment of intestinal BD through 100 weeks.
Read more about safety and effectiveness of adalimumab in intestinal Behçet's disease.
In addition to this article, read other review articles about BD.
Best regards, |
| Related article |
- 1. Could adalimumab be used safely and effectively in intestinal Behçet's disease refractory to conventional therapy?
Park J, Cheon JH. Intest Res. 2017;15(3):263-265
https://doi.org/10.5217/ir.2017.15.3.263 - 2. Optimal diagnosis and disease activity monitoring of intestinal Behçet's disease
Lee HJ, Cheon JH. Intest Res. 2017;15(3):311-317
https://doi.org/10.5217/ir.2017.15.3.311 - 3. Treatment and outcomes: medical and surgical treatment for intestinal Behçet's disease
Hisamatsu T, Hayashida M. Intest Res. 2017;15(3):318-327
https://doi.org/10.5217/ir.2017.15.3.318 - 4. Usefulness of Adalimumab for Treating a Case of Intestinal Behçet's Disease With Trisomy 8 Myelodysplastic Syndrome
Kimura M, Tsuji Y, Iwai M, Inagaki M, Madian A, Yoshino T, Matsuura M, Nakase H. Intest Res. 2015;13(2):166-169
https://doi.org/10.5217/ir.2015.13.2.166
|
|
